Home » Janssen Nabs Breakthrough Therapy Designation for Lung Cancer Treatment
Janssen Nabs Breakthrough Therapy Designation for Lung Cancer Treatment
The FDA granted breakthrough therapy designation to Janssen’s novel antibody JNJ-6372 for treatment of patients with metastatic non-small cell lung cancer whose tumors have epidermal growth factor receptor (EGFR) Exon 20 insertion mutations.
The agency granted the designation based on positive results from a phase 1 trial of JNJ-6372 as a monotherapy and in combination with lazertinib.
Janssen entered into a license and collaboration agreement with Yuhan Corporation for the development of lazertinib.
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May